2026 Global: Cardiac Prosthetic Devices Market-Competitive Review (2032) report
Description
The 2026 Global: Cardiac Prosthetic Devices Market-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cardiac prosthetic devices market by geography and historical trend. The scope of the report extends to sizing of the cardiac prosthetic devices market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Medtronic, Abbott, Boston Scientific, Edwards Lifesciences, and LivaNova are among the ten major companies dominating the cardiac prosthetic devices market, each offering complementary portfolios spanning pacemakers, implantable cardioverter-defibrillators (ICDs), transcatheter and surgical heart valves, and structural heart repair technologies. Medtronic is a global leader known for cardiac rhythm management devices (including leadless pacemakers) and transcatheter therapies, with a broad installed base and strong R&D investment that sustain market leadership. Abbott contributes a wide range of coronary stents, structural heart devices (including mitral repair systems), and haemodynamic monitoring solutions that integrate diagnostics and device therapy, reinforcing its position in both acute and chronic cardiovascular care. Boston Scientific focuses on interventional cardiology and electrophysiology products—stents, left atrial appendage closure devices, and implantable rhythm-management systems—backed by large-scale clinical programs and iterative device improvements to reduce complications and procedural time. Edwards Lifesciences is principally recognized for surgical and transcatheter heart valves and hemodynamic monitoring systems; its transcatheter aortic valve implantation (TAVI) leadership and ongoing valve innovations make it a core structural-heart market player. LivaNova provides cardiac surgery and neuromodulation technologies, including prosthetic valves and perfusion systems used in surgical valve replacement and repair settings, contributing to the surgical prosthetic device supply chain.
BIOTRONIK, Terumo, and CryoLife (Artivion) expand the market across implantable devices, interventional tools, and biologic patch/valve preservation technologies. BIOTRONIK’s implantable pacemakers and defibrillators emphasize remote monitoring and device longevity, supporting ambulatory care and reduced readmissions. Terumo’s vascular intervention devices and delivery systems enable transcatheter therapies and peri-procedural support in structural and coronary interventions, while CryoLife (now Artivion) supplies surgical adjuncts, valve repair materials, and preserved biological tissues that complement prosthetic valve implantation and reoperative cardiac surgery. Siemens Healthineers and GE HealthCare play crucial supporting roles by providing advanced imaging, hemodynamic monitoring, and cath-lab systems that enable precise deployment and follow-up of prosthetic cardiac devices; their imaging platforms and analytics improve patient selection, procedural guidance, and post-procedural surveillance in structural and electrophysiology procedures.
Smaller specialists and niche innovators—such as On-X Life Technologies, SynCardia Systems, Colibri Heart Valve, and emerging firms from China and India—address specific prosthetic segments: mechanical valve technology, total artificial heart solutions, next-generation tissue valves, and lower-cost transcatheter systems for emerging markets. Market dynamics are shaped by clinical trial outcomes, regulatory approvals, and consolidation through acquisitions that accelerate technology transfer (for example, platform acquisitions by large medtech firms), while R&D emphasis on durability, minimization of anticoagulation needs, and less-invasive delivery continues to drive product differentiation and competitive positioning across these ten major companies.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cardiac prosthetic devices market by geography and historical trend. The scope of the report extends to sizing of the cardiac prosthetic devices market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Medtronic, Abbott, Boston Scientific, Edwards Lifesciences, and LivaNova are among the ten major companies dominating the cardiac prosthetic devices market, each offering complementary portfolios spanning pacemakers, implantable cardioverter-defibrillators (ICDs), transcatheter and surgical heart valves, and structural heart repair technologies. Medtronic is a global leader known for cardiac rhythm management devices (including leadless pacemakers) and transcatheter therapies, with a broad installed base and strong R&D investment that sustain market leadership. Abbott contributes a wide range of coronary stents, structural heart devices (including mitral repair systems), and haemodynamic monitoring solutions that integrate diagnostics and device therapy, reinforcing its position in both acute and chronic cardiovascular care. Boston Scientific focuses on interventional cardiology and electrophysiology products—stents, left atrial appendage closure devices, and implantable rhythm-management systems—backed by large-scale clinical programs and iterative device improvements to reduce complications and procedural time. Edwards Lifesciences is principally recognized for surgical and transcatheter heart valves and hemodynamic monitoring systems; its transcatheter aortic valve implantation (TAVI) leadership and ongoing valve innovations make it a core structural-heart market player. LivaNova provides cardiac surgery and neuromodulation technologies, including prosthetic valves and perfusion systems used in surgical valve replacement and repair settings, contributing to the surgical prosthetic device supply chain.
BIOTRONIK, Terumo, and CryoLife (Artivion) expand the market across implantable devices, interventional tools, and biologic patch/valve preservation technologies. BIOTRONIK’s implantable pacemakers and defibrillators emphasize remote monitoring and device longevity, supporting ambulatory care and reduced readmissions. Terumo’s vascular intervention devices and delivery systems enable transcatheter therapies and peri-procedural support in structural and coronary interventions, while CryoLife (now Artivion) supplies surgical adjuncts, valve repair materials, and preserved biological tissues that complement prosthetic valve implantation and reoperative cardiac surgery. Siemens Healthineers and GE HealthCare play crucial supporting roles by providing advanced imaging, hemodynamic monitoring, and cath-lab systems that enable precise deployment and follow-up of prosthetic cardiac devices; their imaging platforms and analytics improve patient selection, procedural guidance, and post-procedural surveillance in structural and electrophysiology procedures.
Smaller specialists and niche innovators—such as On-X Life Technologies, SynCardia Systems, Colibri Heart Valve, and emerging firms from China and India—address specific prosthetic segments: mechanical valve technology, total artificial heart solutions, next-generation tissue valves, and lower-cost transcatheter systems for emerging markets. Market dynamics are shaped by clinical trial outcomes, regulatory approvals, and consolidation through acquisitions that accelerate technology transfer (for example, platform acquisitions by large medtech firms), while R&D emphasis on durability, minimization of anticoagulation needs, and less-invasive delivery continues to drive product differentiation and competitive positioning across these ten major companies.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
